TITLE

GILEAD SUBMITS MAA TO EMEA FOR ADEFOVIR DIPIVOXIL 10 MG

PUB. DATE
May 2002
SOURCE
Worldwide Biotech;May2002, Vol. 14 Issue 5, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Gilead Sciences Inc. has submitted a Marketing Authorisation Application to the European Medicines Evaluation Agency for adefovir dipivoxil drug.
ACCESSION #
6589529

 

Related Articles

  • P & T PORTFOLIO.  // Drug Topics;1/21/2002, Vol. 146 Issue 2, p12 

    Focuses on tenofovir disoproxil fumarate drug from Gilead. Proprietary name; Pharmacology of the drug; Information on the efficacy of the drug; Adverse effects of the drug.

  • Gilead's Harvoni. Investor's Business Daily // Investors Business Daily;2/5/2015, pA02 

    The article offers information on the Cigna hepatitis C genotype 1 drug from Gilead Sciences Inc.

  • Corrections & Clarifications.  // BioWorld Today;6/23/2010, Vol. 21 Issue 120, p2 

    A correction to an article on the drug Clayston from Gilead Sciences Inc. that was published in the June 21, 2010 issue of the periodical "BioWorld Today" is presented.

  • HCV drug tops previous launch records.  // Nature Reviews Drug Discovery;Jun2014, Vol. 13 Issue 6, p405 

    The article reports on the increase of hepatitis C virus polymerase inhibitor sofosbuvir from drug manufacturer Gilead Sciences Inc. to $2.1 billion in the U.S. in 2014.

  • P & T PORTFOLIO.  // Drug Topics;9/15/2003, Vol. 147 Issue 18, p12 

    Highlights the drug Emtriva or emtricitabine from Gilead Sciences Inc. Approved indication; Pharmacological features of the drug; Efficacy; Pharmacokinetic characteristics; Contraindications; Warnings and precautions; Adverse effects.

  • CLINIC ROUNDUP.  // BioWorld Today;6/21/2010, Vol. 21 Issue 118, p4 

    The article announces the accomplishment of one of the co-primary endpoints of noninferiority for mean percent change in forced expiratory volume in one second (FEV1) in the Phase III trial comparing the effectiveness of Cayston, aztreonam, from Gilead Sciences Inc. against the tobramycin...

  • FDA is asked to approve PrEP AIDS regimen.  // Windy City Times;12/28/2011, Vol. 27 Issue 12, p16 

    This article reports on the decision of Gilead Sciences Inc. to file for a U.S. Food and Drug Administration (FDA) approval of its HIV antiretroviral therapy.

  • Off-label Vistide use associated with serious adverse events.  // Reactions Weekly;2/12/2011, Issue 1338, p2 

    The article reports on a Dear Healthcare Professional letter released by Gilead Sciences which indicated that cidofovir should only be administered to treat cytomegalovirus retinitis in patients with AIDS and no renal dysfunction.

  • Cayston approved for CF.  // Monthly Prescribing Reference;Mar2010, Vol. 26 Issue 3, pA19 

    The article reports on the approval of Cayston, an aztreonam solution from Gilead Sciences Inc., for the treatment of improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics